Portfolio Building Block World Pharma and Biotech Index ETF
Schedule of Investments
July 31, 2026 (Unaudited)
| COMMON STOCKS - 99.5% | Shares | Value | ||
| Consumer Staple Products - 0.7% | ||||
| Haleon PLC | 1,237,051 | $ | 6,048,079 | |
| Health Care - 98.8%(a) | ||||
| AbbVie, Inc. | 263,508 | 66,124,698 | ||
| Alnylam Pharmaceuticals, Inc.(b) | 29,349 | 6,031,806 | ||
| Amgen, Inc. | 114,594 | 44,137,025 | ||
| Argenx SE(b) | 13,776 | 11,808,226 | ||
| Astellas Pharma, Inc. | 385,185 | 5,326,911 | ||
| AstraZeneca PLC | 218,231 | 37,098,213 | ||
| Bayer AG | 218,254 | 12,065,932 | ||
| Biogen, Inc.(b) | 32,847 | 6,666,299 | ||
| BioMarin Pharmaceutical, Inc.(b) | 42,787 | 2,568,076 | ||
| Bridgebio Pharma, Inc.(b) | 32,623 | 2,612,776 | ||
| Bristol-Myers Squibb Co. | 453,416 | 29,612,599 | ||
| Chugai Pharmaceutical Co. Ltd. | 138,993 | 6,051,182 | ||
| CSL Ltd. | 122,349 | 10,574,781 | ||
| Daiichi Sankyo Co. Ltd. | 365,422 | 5,892,423 | ||
| Elanco Animal Health, Inc.(b) | 112,523 | 2,967,232 | ||
| Eli Lilly & Co. | 125,960 | 144,707,886 | ||
| Exelixis, Inc.(b) | 54,638 | 2,897,453 | ||
| Galderma Group AG | 11,886 | 2,581,997 | ||
| Genmab A/S(b) | 13,254 | 3,791,520 | ||
| Gilead Sciences, Inc. | 275,847 | 35,918,038 | ||
| GSK PLC | 827,662 | 21,513,554 | ||
| Illumina, Inc.(b) | 33,633 | 6,898,128 | ||
| Incyte Corp.(b) | 44,808 | 5,355,452 | ||
| Insmed, Inc.(b) | 46,715 | 4,606,099 | ||
| Ionis Pharmaceuticals, Inc.(b) | 33,908 | 1,755,417 | ||
| Jazz Pharmaceuticals PLC(b) | 13,582 | 3,434,345 | ||
| Johnson & Johnson | 358,759 | 91,967,870 | ||
| Merck & Co., Inc. | 368,345 | 47,958,519 | ||
| Merck KGaA | 28,653 | 4,719,182 | ||
| Moderna, Inc.(b) | 78,235 | 4,288,843 | ||
| Natera, Inc.(b) | 30,087 | 8,056,095 | ||
| Neurocrine Biosciences, Inc.(b) | 22,193 | 3,701,792 | ||
| Novartis AG | 272,287 | 42,607,421 | ||
| Novo Nordisk A/S - Class B | 708,402 | 33,420,589 | ||
| Otsuka Holdings Co. Ltd. | 91,224 | 6,359,469 | ||
| Pfizer, Inc. | 1,266,224 | 31,668,262 | ||
| Regeneron Pharmaceuticals, Inc. | 22,298 | 17,005,124 | ||
| Revolution Medicines, Inc.(b) | 39,316 | 7,372,929 | ||
| Roche Holding AG - Class BR | 6,684 | 2,962,589 | ||
| Roche Holding AG | 103,199 | 45,103,722 | ||
| Roivant Sciences Ltd.(b) | 107,395 | 3,641,764 | ||
| Royalty Pharma PLC - Class A | 83,179 | 4,860,149 | ||
| Sandoz Group AG | 90,803 | 7,380,515 | ||
| Sanofi SA | 241,243 | 20,670,041 | ||
| Shionogi & Co. Ltd. | 160,184 | 2,926,018 | ||
| Takeda Pharmaceutical Co. Ltd. | 343,901 | 11,907,214 | ||
| Teva Pharmaceutical Industries Ltd.(b) | 257,121 | 9,127,264 | ||
| UCB SA | 26,737 | 6,856,903 | ||
| United Therapeutics Corp.(b) | 9,404 | 4,868,545 | ||
| Vertex Pharmaceuticals, Inc.(b) | 56,247 | 26,835,444 | ||
| Viatris, Inc. | 256,625 | 4,506,335 | ||
| Zoetis, Inc. - Class A | 93,270 | 7,208,838 | ||
| 940,979,504 | ||||
| TOTAL COMMON STOCKS (Cost $931,125,013) | 947,027,583 | |||
| SHORT-TERM INVESTMENTS - 0.3% | ||||
| Money Market Funds - 0.3% | Shares | Value | ||
| Dreyfus Treasury Securities Cash Management, 3.56%(c) | 3,258,955 | 3,258,955 | ||
| TOTAL SHORT-TERM INVESTMENTS (Cost $3,258,955) | 3,258,955 | |||
| TOTAL INVESTMENTS - 99.8% (Cost $934,383,968) | $ | 950,286,538 | ||
| Other Assets in Excess of Liabilities - 0.2% | 1,953,682 | |||
| TOTAL NET ASSETS - 100.0% | $ | 952,240,220 |
Percentages are stated as a percent of net assets.
| PLC | Public Limited Company |
| (a) | To the extent that the Fund invests more heavily in a particular industry or sector of the economy, its performance will be especially sensitive to developments that significantly affect those industries or sectors. |
| (b) | Non-income producing security. |
| (c) | The rate shown represents the 7-day annualized effective yield as of July 31, 2026. |